Privi Speciality Chemicals Limited (PSCL) will hold an NCLT-convened meeting on October 27, 2026, to seek shareholder approval for the amalgamation of Privi Fine Sciences and Privi Biotechnologies. The move aims to streamline group operations and create synergies. Shareholders will vote on an exchange ratio of 1 PSCL share for every 135 Privi Fine Sciences shares. The process involves remote e-voting starting October 22, 2026.
Privi Speciality Chemicals NCLT Meeting Set for October 27
1:135 share exchange ratio proposed for merger with Privi Fine Sciences
FY 2025-26 Consolidated PAT reported at Rs 316.72 crore
Reader Takeaway: Simplification of corporate structure aims for operational synergy but introduces equity dilution for existing shareholders.
What just happened
Privi Speciality Chemicals Limited (PSCL) has officially scheduled an NCLT-convened shareholder meeting for October 27, 2026. The meeting will be conducted via video conferencing to seek approval for the merger of Privi Fine Sciences Private Limited and Privi Biotechnologies Private Limited into PSCL. This follows a formal NCLT order issued on September 7, 2026, which directs the company to formalize the amalgamation process.
Why this matters
The consolidation of these group entities is intended to optimize operational capabilities and eliminate redundant compliance requirements across the business. By merging these units, management expects to enhance overall market competitiveness and create a more efficient organizational framework. Shareholders will be determining the final path for this integration, which hinges on receiving the requisite majority approval during the October meeting.
Consideration Details
Under the proposed scheme, shareholders of Privi Fine Sciences will receive one fully paid-up equity share of PSCL (face value Rs 10) for every 135 equity shares they hold. In the case of Privi Biotechnologies, which is already a wholly owned subsidiary of PSCL, the share capital will be cancelled without any new issuance, effectively neutralizing its separate corporate identity.
Context Metrics (FY 2025-26)
- Standalone Revenue: Rs 2,455.53 crore
- Standalone PAT: Rs 357.44 crore
- Consolidated Revenue: Rs 2,563.69 crore
- Consolidated PAT: Rs 316.72 crore
What to track next
Investors should monitor the voting outcome which concludes on October 26, 2026. Following the shareholder vote, the scheme requires final sanction from the NCLT before it can become legally effective. Shareholders should also remain aware of the potential dilution impact on existing equity resulting from the new share issuance to the transferor company's shareholders.